Literature DB >> 12434945

Stress, coping, and immune function in breast cancer.

Linda J Luecken1, Bruce E Compas.   

Abstract

Research has found suggestive links between emotional distress and immune and neuroendocrine measures in cancer patients. Furthermore, several studies have reported that participation in psychological support groups is associated with better health outcomes for cancer patients. However, controversy exists surrounding these findings, and the mechanisms behind such effects are unclear. This article integrates current evidence from several lines of research concerning the relations among coping, psychological adjustment, cortisol and immune function, and disease progression in breast cancer patients. A biopsychosocial model is evaluated in which coping and psychological adjustment are associated with alterations in cortisol levels, immune function, and potential long-term medical outcomes in breast cancer patients. Although strong evidence suggests that coping and psychosocial intervention can improve psychological outcomes for breast cancer patients, potential effects on physiological outcomes remain speculative.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12434945     DOI: 10.1207/S15324796ABM2404_10

Source DB:  PubMed          Journal:  Ann Behav Med        ISSN: 0883-6612


  15 in total

1.  Effects of childhood trauma exposure and cortisol levels on cognitive functioning among breast cancer survivors.

Authors:  Charles Kamen; Caroline Scheiber; Michelle Janelsins; Booil Jo; Hanyang Shen; Oxana Palesh
Journal:  Child Abuse Negl       Date:  2017-08-14

2.  Changes in light-, moderate-, and vigorous-intensity physical activity and changes in depressive symptoms in breast cancer survivors: a prospective observational study.

Authors:  Benjamin D Sylvester; Rashid Ahmed; Steve Amireault; Catherine M Sabiston
Journal:  Support Care Cancer       Date:  2017-05-11       Impact factor: 3.603

Review 3.  Psychosocial interventions addressing the needs of Black women diagnosed with breast cancer: a review of the current landscape.

Authors:  Nicole Ennis Whitehead; Lauren E Hearn
Journal:  Psychooncology       Date:  2014-07-17       Impact factor: 3.894

4.  [Psychiatric psychotherapeutic interventions in breast cancer inpatients: a contribution to liaison-consultation psychiatry].

Authors:  M Grube; H Weigand-Tomiuk
Journal:  Nervenarzt       Date:  2014-11       Impact factor: 1.214

5.  Stress, coping and cognitive deficits in women after surgery for breast cancer.

Authors:  Stephanie A Reid-Arndt; Cathy R Cox
Journal:  J Clin Psychol Med Settings       Date:  2012-06

6.  Tamoxifen is an estrogen antagonist on gonadotropin secretion and responsiveness of the hypothalamic-pituitary- adrenal axis in female monkeys.

Authors:  M E Wilson; D Mook; F Graves; J Felger; I F Bielsky; K Wallen
Journal:  Endocrine       Date:  2003-12       Impact factor: 3.633

7.  Examination of the construct validity of the Swedish version of Hospital Anxiety and Depression Scale in breast cancer patients.

Authors:  Fredrik Saboonchi; Agneta Wennman-Larsen; Kristina Alexanderson; Lena-Marie Petersson
Journal:  Qual Life Res       Date:  2013-04-09       Impact factor: 4.147

Review 8.  Cancer, coping, and cognition: a model for the role of stress reactivity in cancer-related cognitive decline.

Authors:  Charissa Andreotti; James C Root; Tim A Ahles; Bruce S McEwen; Bruce E Compas
Journal:  Psychooncology       Date:  2014-10-06       Impact factor: 3.894

Review 9.  Psychological intervention and health outcomes among women treated for breast cancer: a review of stress pathways and biological mediators.

Authors:  Bonnie A McGregor; Michael H Antoni
Journal:  Brain Behav Immun       Date:  2008-08-22       Impact factor: 7.217

10.  Sensitivity and specificity of the Distress Thermometer for depression in newly diagnosed breast cancer patients.

Authors:  Mark T Hegel; E Dale Collins; Stephen Kearing; Karen L Gillock; Caroline P Moore; Tim A Ahles
Journal:  Psychooncology       Date:  2008-06       Impact factor: 3.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.